Parkinson's disease (PD) is the second most common neurodegenerative disorder, characterized by a complex pathogenesis involving the interplay of multiple molecular and cellular pathways. In recent years, metabolic dysregulation and neuroinflammation have been recognized as key contributors to PD...
Targeted LC-MS metabolomic profiling was performed on plasma samples from a validation cohort comprising 20 patients with Parkinson's disease and 20 healthy controls. The study aimed to verify altered circulating bile acid levels identified in the discovery cohort, assess correlations between bil...
Parkinson's disease (PD) is a common neurodegenerative disorder. It is marked by motor dysfunction and cognitive decline. In recent years, scientific studies have found that PD's pathogenesis may be tied to an imbalance in the gut microbiota. This offers new perspectives for PD treatment. Modulat...
Objectives: Patients with Parkinson's disease (PD) with probable Rapid eye movement sleep Behavior Disorder (RBD) (PD-RBD), a specific subtype of PD, is characterized by the presence of more severe motor and non-motor symptoms. This study aimed to elucidate the characteristics and interactions of...
Nicotinamide adenine dinucleotide (NAD) replenishment therapy using nicotinamide riboside (NR) shows promise for Parkinson’s disease (PD) and other neurodegenerative disorders. However, the optimal dose of NR remains unknown, and doses exceeding 2000 mg daily have not been tested in humans. To ev...